Clinical Trial Update: Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)] [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating pembrolizumab plus Bacillus Calmette-Guérin as first-line therapy for high-risk T1 non-muscle-in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Upper Tract Urothelial Carcinoma

Drugs mentioned

• BCG vaccine (Bacillus Calmette-Guérin)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Bladder Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING